Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 1, 1996, Pages 45-52

  Ansorg, R ^a   Von Recklinghausen, G ^a   Heintschel von Heinegg, E ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIFOAMING AGENT; ANTIFUNGAL AGENT; DIMETHYL SULFOXIDE; GABEXATE MESILATE; KETOCONAZOLE; PROTEINASE INHIBITOR; SCAVENGER; SIMETHICONE;

ANTIBIOTIC SENSITIVITY; ARTICLE; GROWTH INHIBITION; HELICOBACTER PYLORI; NONHUMAN;

ANTIFOAMING AGENTS; ANTIFUNGAL AGENTS; DIMETHYL SULFOXIDE; GABEXATE; HELICOBACTER PYLORI; HUMANS; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; SERINE PROTEINASE INHIBITORS; SIMETHICONE;

EID: 0030009715     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.1.45     Document Type: Article

References (29)

1. Auteri, A. (1991). Simethicone. In Drugs in Gastroenterology (Brage, P. C., Guslandi, M. & Tittobello, A., Eds), pp. 433-46. Raven Press, New York.
2. Bayerdörffer, E., Mannes, G. A., Sommer, A., Hochter, W., Weingart, J., Hatz, R. et al. (1992). High dose omeprazole treatment combined with amoxycillin eradicates Helicobacter pylori. European Journal of Gastroenterology and Hepatology 4, 697-702.
3. Blaser, M. J. (1992). Helicobacter pylori: its role in disease. Clinical Infectious Diseases 15, 386-93.
4. Büchler, M., Malfertheiner, P., Uhl, W., Schölmerich, J., Stöckmann, F., Adler, G. et al. (1993). Gabexate mesilate in human acute pancreatitis. Gastroenterology 104, 1165-70.
5. Buck, G. E. (1990). Campylobacter pylori and gastroduodenal disease. Clinical Microbiological Reviews 3, 1-12.
6. 2 by gabexate mesilate, camostate, and aprotinine. Klinische Wochenschrift 67, 149-52.
7. Goodwin. C. S. (1993). Overview of Helicobacter pylori gastritis, peptic ulcer, and gastric cancer and the possible development of an H. pylori vaccine. In Helicobacter pylori: Biology and Clinical Practice (Goodwin, C. S. & Worsley, B. W., Eds), pp. 431-44. CRC Press, Boca Raton.
8. Groitl, H., Schmidt, A. & Upmeyer, H.-J. (1994). Treatment of gastric ulcers using a specific formulation of polydimethylsiloxane/(UCD). World Congress of Gastroenterology, Abstracts H: Poster presentations. Los Angeles.
9. Heeres, J., Backx, L. J., Mostmans, J. H. & Van Cutsem, J. (1979). Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. Journal of Medical Chemotherapy 22, 1003-5.
10. Heldwein, W., Sommerlatte, T., Hasford, J., Lehnert, P., Littig, G. & Müller-Lissner, S. (1987). Evaluation of the usefulness of dimethicone and/or senna extract in improving the visualization of abdominal organs. Journal of Clinical Ultrasound 15, 455-8.
11. Hentschel, E., Brandstätter, G., Dragosics, B., Hirschl, A. M., Nemec, H., Schütze, K. et al. (1993). Effect of ranitidine and amoxicillin plus metronidazole in the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. New England Journal of Medicine 328, 308-12.
12. Hesse, B., Lankisch, P. G. & Kunze, H. (1984). Effects of the serine protease inhibitor gabexate mesilate on purified pancreatic phospholipase A:. Pharmacological Research Communications 16, 637-45.
13. Kucers, A. & Bennett, N. McK. (1987). The Use of Antibiotics, pp. 1506-27, W. Heinemann, London.
14. Lee, A., Fox, J. & Hazell, S. (1993). Pathogenicity of Helicobacter pylori: a perspective. Infection and Immunity 61, 1601-10.
15. Mitchell, H. M. (1993). The epidemiology of Helicobacter pylori infection and its relation to gastric cancer. In Helicobacter pylori: Biology and Clinical Practice (Goodwin, C. S. & Worsley, B. W., Eds), pp. 95-114. CRC Press, Boca Raton.
16. National Institute of Health (NIH) Consensus Development Conference. (1994). Helicobacter pylori in peptic ulcer disease. Journal of the American Medical Association 272, 65-9.
17. Niedner, N. (1982). Dimethylpolysiloxan bei der Meteorismustherapie-Doppelblinduntersuchung zur Dosis-Wirkungs-Beziehung. Therapiewoche 32, 5390-4.
18. O'Morain, C. & Buckley, M. (1994). Helicobacter pylori associated gastroduodenal diseases. Antiinfective Drugs and Chemotherapy 12, 9-11.
19. Ottlecz, A., Romero, J. J., Hazell, S. L., Graham, D. Y. & Lichtenberger, L. M. (1993). Phospholipase activity of Helicobacter pylori and its inhibition by bismuth salts. Digestive Diseases and Sciences 38, 2071-80.
20. Parsonnet, J., Friedman, G. D., Vandersteen, D. P., Chang, Y., Voeglman, J. H., Orentreich, N. et al. (1991). Helicobacter pylori infection and risk of gastric carcinoma. New England Journal of Medicine 326, 1127-31.
21. Parsonnet, J., Hansen, S., Rodriguez, L., Gelb, A. B., Warnke, R. A., Jellum, E. et al. (1994). Helicobacter pylori infection and gastric lymphoma. New England Journal of Medicine 330, 1267-71.
22. Rautelin, H., Vaara, M., Renkonen, O.-V., Kosunen, T. U. & Seppalä, K. (1992). In vitro activity of antifungal azoles against Helicobacter pylori. European Journal of Clinical Microbiology and Infectious Diseases 11, 273-4.
23. Salim, A. S. (1990). Oxygen-derived free radicals and the prevention of duodenal ulcer relapse: a new approach. American Journal of Medical Science 300, 1-6.
24. Talley, N. J. & Noack, K. B. (1993). The worldwide prevalence of Helicobacter pylori: asymptomatic infection and clinical states associated with infection in adults. In Helicobacter pylori: Biology and Clinical Practice (Goodwin, C. S. & Worsley, B. W., Eds), pp. 64-83. CRC Press, Boca Raton.
25. Telford, J. L., Covacci, A., Ghiara, P., Montecucco, C. & Rappnoli, R. (1994). Unravelling the pathogenetic role of Helicobacter pylori in peptic ulcer: potential new therapies and vaccines. Trends in Biotechnology 12, 420-6.
26. von Recklinghausen, G., Di Maio, C. & Ansorg, R. (1992). Activity of the antimycotic ketoconazole against Helicobacter pylori. Journal of Antimicrobial Chemotherapy 30, 238-40.
27. von Recklinghausen, G., Di Maio, C. & Ansorg, R. (1993). Activity of antibiotics and azole antimycotics against Helicobacter pylori. Zentralblatt für Bakteriologie 280, 279-85.
28. Wotherspoon, A. C., Ortiz-Hidalgo, C., Falzon, M. R. & Isaacson, P. G. (1991). Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338, 1175-6.
29. Yang, C.-Y., Chang-Chien, C.-S. & Liaw, Y.-F. (1987). Controlled trial of protease inhibitor gabexate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 2, 698-700.